Supernus Pharmaceuticals SUPN Deferred Tax Assets and Other Non-Current Assets
Deferred Tax Assets and Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's deferred tax assets and other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's deferred tax assets and other non-current assets?
- Supernus Pharmaceuticals (SUPN) reported deferred tax assets and other non-current assets of $56.45M in Q1 2026.
- How has Supernus Pharmaceuticals's deferred tax assets and other non-current assets changed year-over-year?
- Supernus Pharmaceuticals's deferred tax assets and other non-current assets increased by 93.2% year-over-year, from $29.22M to $56.45M.
- What is the long-term trend for Supernus Pharmaceuticals's deferred tax assets and other non-current assets?
- Over 5 years (2020 to 2025), Supernus Pharmaceuticals's deferred tax assets and other non-current assets has grown at a 8.1% compound annual growth rate (CAGR), from $43.25M to $63.8M.